Cargando…

Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction

The prevalence of heart failure with preserved ejection fraction (HFpEF) is constantly increasing and no evidence-based pharmacological treatment option is available. While exercise training (ET) improves diastolic function, its metabolic mechanisms in HFpEF are unclear. We assessed the metabolic re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahls, Martin, Friedrich, Nele, Pietzner, Maik, Wachter, Rolf, Budde, Kathrin, Hasenfuß, Gerd, Nauck, Matthias, Pressler, Axel, Felix, Stephan B., Edelmann, Frank, Halle, Martin, Dörr, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572398/ https://www.ncbi.nlm.nih.gov/pubmed/31035733 http://dx.doi.org/10.3390/jcm8050591

Ejemplares similares

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction
por: Bobenko, Anna, et al.
Publicado: (2017)

Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
por: Hashemi, Djawid, et al.
Publicado: (2020)

Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction
por: Nolte, Kathleen, et al.
Publicado: (2019)

Influence of baseline parameters on one‐year physical, mental, and health‐related quality of life in patients with heart failure and preserved ejection fraction
por: Fitz, Judith, et al.
Publicado: (2021)

Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex‐DHF pilot study
por: Trippel, Tobias Daniel, et al.
Publicado: (2016)

Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP
por: Masuch, Annette, et al.
Publicado: (2018)

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction
por: Edelmann, Frank, et al.
Publicado: (2011)

Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction
por: Bobenko, Anna, et al.
Publicado: (2020)

The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
por: Trippel, Tobias Daniel, et al.
Publicado: (2021)

Determinants of submaximal exercise capacity in patients at risk for heart failure with preserved ejection fraction—results from the DIAST‐CHF study
por: Stahrenberg, Raoul, et al.
Publicado: (2015)

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
por: Schnelle, Moritz, et al.
Publicado: (2021)

The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction
por: Stahrenberg, Raoul, et al.
Publicado: (2010)

Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study
por: Eidizadeh, Abass, et al.
Publicado: (2022)

Molecular Fingerprints of Iron Parameters among a Population-Based Sample
por: Kaul, Anne, et al.
Publicado: (2018)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Zach, Veronika, et al.
Publicado: (2020)

Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction
por: Edelmann, Frank
Publicado: (2015)

Low-grade inflammation is associated with a heterogeneous lipoprotein subclass profile in an apparently healthy population sample
por: Pontzen, Daniel L., et al.
Publicado: (2023)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials
por: Kresoja, Karl-Patrik, et al.
Publicado: (2023)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Urinary metabolomics reveals glycemic and coffee associated signatures of thyroid function in two population-based cohorts
por: Friedrich, Nele, et al.
Publicado: (2017)

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
por: Budde, Heidi, et al.
Publicado: (2022)

Circulating Irisin Concentrations Are Associated with a Favourable Lipid Profile in the General Population
por: Oelmann, Simon, et al.
Publicado: (2016)

A Thyroid Hormone-Independent Molecular Fingerprint of 3,5-Diiodothyronine Suggests a Strong Relationship with Coffee Metabolism in Humans
por: Pietzner, Maik, et al.
Publicado: (2019)

Exercise tolerance in asymptomatic patients with moderate-severe valvular heart disease and preserved ejection fraction
por: Olaf, Schulz, et al.
Publicado: (2012)

Arginine metabolism and nitric oxide turnover in the ZSF1 animal model for heart failure with preserved ejection fraction
por: Büttner, Petra, et al.
Publicado: (2021)

Associations between adipose tissue volume and small molecules in plasma and urine among asymptomatic subjects from the general population
por: Otto, Lerina, et al.
Publicado: (2020)

Muscular changes in animal models of heart failure with preserved ejection fraction: what comes closest to the patient?
por: Goto, Keita, et al.
Publicado: (2020)

Metabolic signature associated with parameters of the complete blood count in apparently healthy individuals
por: Masuch, Annette, et al.
Publicado: (2019)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

L-Arginine and SDMA Serum Concentrations Are Associated with Subclinical Atherosclerosis in the Study of Health in Pomerania (SHIP)
por: Bahls, Martin, et al.
Publicado: (2015)

Peak O(2)‐pulse predicts exercise training‐induced changes in peak V̇O(2) in heart failure with preserved ejection fraction
por: Mueller, Stephan, et al.
Publicado: (2022)

Association of plasma chemerin with all-cause and disease-specific mortality – results from a population-based study
por: Noppes, Katharina, et al.
Publicado: (2023)

Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction
por: Maffeis, Caterina, et al.
Publicado: (2020)

High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia
por: Stahrenberg, Raoul, et al.
Publicado: (2013)

Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction
por: Deis, T., et al.
Publicado: (2021)

One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction
por: Kaye, David M., et al.
Publicado: (2016)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1k0iakv72r3g3lir7ad0ph886o